Compare Inovio Pharmaceuticals Inc (INO) vs Centrus Energy Corp (LEU) Price & Performance

Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.

The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.

Centrus Energy (LEU) trades at $141.28, down 3.98% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics (P/E 75.18, P/S 6.68) but benefits from strong nuclear energy tailwinds and multiple HALEU supply contracts. Recent news highlights Centrus as a key player in the domestic nuclear fuel supply chain, with analyst consensus pointing to significant upside potential from current levels.

The investment case balances high execution risk against substantial growth opportunities in nuclear fuel enrichment. While profitability metrics show pressure (net margin declining to 10.23%), the company's strategic positioning in HALEU production and federal support create compelling long-term potential. Key risks include operational execution, valuation sensitivity, and nuclear industry adoption timelines.